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Abstract  1 
Graphene offers promising advantages for biomedical applications. However, adoption of 2 
graphene technology in biomedicine also poses important challenges in terms of understanding 3 
cell responses, cellular uptake or the intracellular fate of soluble graphene derivatives. In the 4 
biological microenvironment graphene nanosheets might interact with exposed cellular and 5 
subcellular structures resulting in unexpected regulation of sophisticated biological signaling. 6 
More broadly, biomedical devices based on the design of these 2D planar nanostructures for 7 
interventions in the central nervous system (CNS) requires an accurate understanding of their 8 
interactions with the neuronal milieu. Here, we describe the previously unreported ability of 9 
graphene oxide nanosheets to down-regulate neuronal signaling without affecting cell viability. 10 
 11 
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Text  16 
 Graphene is a 2D plate-like material consisting of sp2-hybridized carbon atoms organized 17 
in a hexagonal lattice and characterized by, among other properties, high electrical conductivity 18 
and mechanical flexibility1-3. In addition to the successful exploitation of graphene and 19 
graphene-based materials in an increasing number of industrial products, current applications of 20 
graphene hold the potential to revolutionize specific areas of medicine2-6. Biomedical 21 
developments in general, and in neurology in particular, are focusing on few-layer graphene 22 
sheets to manufacture novel bio-devices, including biosensors, interfaces, tissue scaffolds, drug 23 
delivery and gene therapy vector systems4. Successful design of multifunctional neuro-devices 24 
based on graphene will expose brain cells and neuronal circuits directly to this material by 25 
injection or implantation4,7. In this context, the exploration of the interactions between graphene 26 
nano- and micro-sheets with the sophisticated signaling machinery of nerve cells, with a 27 
particular focus on potential graphene flake interactions with the hydrophobic membrane 28 
domains, is of great importance1,8,9. Such interactions may favor graphene translocation, or 29 
adhesion to cell membranes8,10, potentially interfering with exquisite membrane activities, such 30 
as the exocytic and endocytic trafficking systems, crucial to physiological synaptic 31 
transmission8,11.  32 
 Here we explore for the first time by patch clamp and fluorescence imaging the ability of 33 
graphene (GR) and graphene oxide (GO) nanosheets to interfere with synaptic signaling once 34 
hippocampal cultured neurons are exposed for one week to a growth medium containing thin 35 
sheets of such materials at 1 or 10 µg/mL (concentrations reported not to induce cell death12-14). 36 
 3 
We further investigated whether, in the absence of explicit cell toxicity, such materials affected 1 
the ability of astrocytes to release synaptic-like microvesicles15 (MV) in pure glial cultures. Our 2 
results describe the potential of GO nanosheets to alter different modes of inter-neuronal 3 
communication systems in the CNS hinting at opportunities for novel neuromodulatory 4 
applications or highlighting subtle, but potentially unwanted, subcellular interactions. 5 
 6 
Results and Discussion  7 
To address the issue of prolonged exposure of a functional brain network to graphene 8 
sheets we used different materials. Graphene oxide sheets of large and small lateral dimensions 9 
(l-GO and s-GO, respectively) were synthesized using a modified-Hummers method (see 10 
Supporting Information). Following the reaction, the GO-gel like upper layer was extracted 11 
carefully by using warm water, resulting in the large GO (l-GO). Final concentrations ranged 12 
between 1 and 2mg/mL were obtained with a yield of ca. 10%. l-GO was freeze-dried, 13 
reconstituted in water for injection, sonicated for 5 mins and centrifuged at room temperature to 14 
generate the small GO (s-GO).The lateral dimension of GO sheets was controlled by drying and 15 
sonicating the l-GO to obtain the s-GO sheets, that were always at least one order of magnitude 16 
smaller, without introducing any significant changes among their surface properties (see Table 17 
S1). 18 
The GO dispersions in aqueous media were homogenous, of brownish color and stable at 19 
room temperature for more than 6 months. The physicochemical characterization of the l-GO and 20 
s-GO dispersions is shown in Figure 1 (a-f), and in the Supporting Information Figure S1 and S2. 21 
Their structural properties (lateral dimension and thickness) were studied by optical microscopy, 22 
transmission electron microscopy (TEM) and atomic force microscopy (AFM). Optical 23 
properties were studied by UV-Vis and fluorescence spectroscopy. Raman spectroscopy and 24 
laser Doppler electrophoresis (measuring ζ–potential) were used to assess the surface properties 25 
of the GO materials. Their Raman spectrum showed D and G bands at 1319 cm-1 and 1596 cm-1, 26 
respectively, characteristic of most poly-aromatic hydrocarbons. The D to G band intensity ratio 27 
(ID/IG) was calculated at 1.3, corresponding to the metric of disorder in the graphitic structure. 28 
The surface charge measured with a Zetasizer instrument showed an average ζ–potential of -50 29 
mV, indicating flakes of high negative surface charge. To elucidate the degree of surface 30 
functionalization, thermo-gravimetric analysis (TGA) and X-ray photoelectron spectroscopy 31 
(XPS) survey spectra were performed to quantify the purity of the GO (> 99%) and the C:O ratio 32 
XPS high resolution C1s spectra were recorded to elucidate the contribution of individual 33 
functional groups such as carboxylic, carbonyl, epoxide and hydroxyl (Table S2b). All fittings 34 
shown were performed using the CasaXPS software and the different regions were assigned 35 
according to Nist XPs and lasurface databases. Deconvolution XPS spectra and assignment of 36 
 4 
the functional groups indicated that hydroxyls were the least abundant species in the GO material 1 
produced (see also Supporting Information, Table S2a). 2 
 Aqueous dispersions of graphene (GR) flakes were prepared using ball-milling for the 3 
exfoliation of graphite through interaction with melamine, as previously described16,17 (see 4 
Supporting Information). Due to the GR preparation process, graphene dispersions can contain 5 
traces of melamine. In order to determine the exact amount of these traces, final graphene 6 
dispersions (0.09 mg/mL) were evaluated by elemental analysis indicating 0.9 ppm of melamine. 7 
Experiments that involved incubation in neurons also included controls exposed to equal 8 
amounts of melamine alone (see Supporting Information). The physicochemical characterization 9 
of GR dispersions is shown in Figure S3. The lateral size, studied by TEM, was found to range 10 
between 500nm-3µm (Figure S3a-b). Optical properties were studied by UV-Vis absorption 11 
spectroscopy. Dispersions were diluted and their UV-Vis absorption spectra were recorded 12 
(Figure S3). The spectra are featureless in the Vis–NIR region, as expected. The absorbance at 13 
660 nm, divided by cell length, is plotted against the concentration exhibiting Lambert-Beer 14 
behavior (Figure S3d). Raman spectroscopy revealed differences between the GO and GR. 15 
Graphene exhibits G and 2D modes around 1573 and 2700 cm-1, that satisfy Raman selection 16 
rules, while the D peak, around 1345 cm-1 requires a defect for its activation (Figure S3e). The 17 
D to G band intensity ratio was calculated at different locations, giving a significant low value 18 
(0.22) in comparison with GO. TGA was also used to quantify the functionalization degree of 19 
GR. The low weight loss observed in GR (7%) corroborated the low quantity of oxygen groups 20 
generated by the exfoliation process (Figure S3f). 21 
 We used hippocampal neurons isolated and cultured for 8-10 days in vitro (DIV). 22 
Primary neuronal cultures were incubated at 2 DIV in the presence of GR or s-GO (at 1 µg/mL 23 
and 10 µg/mL; see Supporting Information) maintained for 6 to 8 days and afterwards visually 24 
identified neurons were patch clamped under voltage clamp. Hippocampal neuron maturation 25 
and viability were assessed using single-cell recordings (see Supporting Information) to measure 26 
the cell passive membrane properties that are accepted indicators of neuronal health18-20 that 27 
allowed comparison among the recorded cells. These parameters (membrane capacitance and 28 
input resistance) displayed similar values in all treatment conditions (summarized in Table 1).  29 
 30 
Table 1.  Neuronal passive membrane properties upon GR and s-GO exposure (1 µg/mL and 10 µg/mL 31 
respectively). 32 
  33 
 Capacitance (pF) Input Resistance (MΩ) 
Control1         n=24 59 ± 4 976 ± 138 
 5 
Melamine1    n=28 46 ± 5 1036 ± 132 
s-GO1      n= 27 62 ± 8 876 ± 145 
GR1     n=30 50 ± 5 1029 ± 161 
Control10     n=20 57 ± 7 744 ± 82 
Melamine10    n=25 72 ± 16 717 ± 106 
s-GO10    n=18 67 ± 6 997 ± 156 
GR10     n=25 59 ± 18 1223 ± 501 
 1 
 To investigate synapse formation and activity after in vitro growth of neurons, we 2 
monitored the occurrence of spontaneous postsynaptic currents (PSCs). The appearance of PSCs 3 
provided clear evidence of functional synapse formation and it is a widely accepted index of 4 
network efficacy21,22. 5 
 6 
Figure 11 
 2 
Figure 1.  Characterization of small graphene oxide (s-GO) of biological-grade; graphene oxide exposure at high 3 
concentration influences synaptic function. In (a-f) physicochemical characterization of s-GO: (a) TEM micrograph 4 
(scale bar 1 µm). (b) AFM height image (scale bar 1 µm), (c) lateral dimension distribution and (d) thickness 5 
distribution analysis. (e) Normalized Raman spectrum. (f) TGA analysis. In (g) graphene oxide exposure at high 6 
concentration influences synaptic function. Spontaneous synaptic activity recorded from hippocampal cultures in 7 
control, melamine, s-GO and GR-treated cultures at 1 μg/mL (top traces) and 10 μg/mL (bottom traces) grown for 8 8 
to 10 DIV. PSCs were detected at -56 mV holding potential.  Bottom plots represent pooled data and summarize 9 
average PSCs amplitude and frequency: note the reduction in s-GO-treatment (10 μg/mL, final concentration) of 10 
PSCs frequency (*** = P < 0.001 Student’s test, data are mean ± SEM). 11 
 12 
 Figure 1g, shows representative current tracings of the recorded electrical activity. In 13 
neurons exposed to low (1 µg/mL) s-GO and GR, spontaneous synaptic activity was not 14 
 7 
affected. In fact, measured PSC amplitude and frequency in s-GO and GR (79 ± 7 pA and 2.5 ± 1 
0.4 Hz n=27 and 77 ± 8 pA and 3 ± 0.5 Hz, n= 30, respectively) were comparable to the 2 
corresponding control and control-melamine values (87 ± 8 pA and 2.3 ± 0.3 Hz, control, n=24; 3 
80 ± 15 pA and 2.3 ± 0.5 Hz melamine n= 28; plots in Figure 1 (g)). In all tests, cell parameters 4 
measured in melamine were comparable to those expressed by control neurons (Figure 1 (g) 5 
bottom plots), thus the impact on cells of such a contaminant at the estimated concentration is 6 
negligible.  7 
When investigating the impact of higher graphene doses (10 µg/mL) we detected a 8 
significant difference (P < 0.001; Student’s t-test) in PSC frequency when comparing control 9 
neurons (2.0 ± 0.1 Hz control, n= 20) with s-GO treated ones (0.6 ± 0.1 Hz, n= 18), while in 10 
melamine and GR, PSC frequency values remained unchanged (2.5 ± 0.7 Hz melamine, n= 25 11 
and 2.8 ± 1.1 Hz GR; n= 25). In all treatments studied, the amplitude values of the PSCs were 12 
never affected (data are summarized in Figure 1 (g) plots). We further tested synaptic responses 13 
when neurons were treated (1 and 10µg/mL) with a commercially available GO provided by an 14 
industrial partner (A-GO; Supporting Information and Figures S4). Similar reduction in PSC 15 
frequency (Figure S5) was detected that validated the observation that GO nanosheets, 16 
differently to GR flakes, specifically interfered with synapses in cultured neurons, regardless of 17 
the starting material. 18 
  19 
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Figure 2 1 
 2 
Figure 2.   s-GO exposure at high concentration impaired network activity without changing network size. In (a) 3 
immunofluorescence images are shown to visualize neurons and glial cells in the 4 different conditions (anti β-4 
tubulin III, in red, left panels; anti-GFAP, in green, right panels, in all nuclei are visualized by DAPI in blue) 5 
(samples are for the 10 μg/mL protocol; scale bar 50 μm). The plots summarize neuronal (left) and glial (right) 6 
densities in all conditions. In (b) repetitive Ca2+-oscillations spontaneously (left panel) or bicuculline-induced (right 7 
panel) recorded in hippocampal cultures at 8 to 10 DIV (from each field sample recordings of 2 cells were selected). 8 
Histograms summarize the percentage of spontaneous active cells (middle) and the average values of the inter-event-9 
interval (IEI; right) in standard saline (Krebs) and in the presence of bicuculline (*** = P < 0.001 Student’s-t-test, 10 
data are mean ± SEM).    11 
 12 
 The impact of 10 µg/mL s-GO on synaptic activity was not related to a decreased 13 
number of surviving neurons in the presence of s-GO. In fact, we determined the cellular 14 
composition of control and s-GO treated hippocampal cultures using immunofluorescence 15 
markers23 for astrocytes (GFAP) and neurons (β-tubulin III). We observed both β-tubulin III and 16 
GFAP immunoreactive cells in all growing conditions (Figure 2 (a)) and both cell groups were 17 
represented in a comparable proportion in all treatment groups (quantified by measuring the cell 18 
 9 
density in Figure 2 (a), (n=13 visual field per condition, 3 different culture series). Thus s-GO at 1 
higher concentrations specifically altered synapse formation and/or function without affecting 2 
cell survival or the global network size.  3 
 To gain more insight into such processes we further investigated s-GO-treated (10 4 
µg/mL) cultures. We specifically addressed the distribution of neuronal excitation by measuring 5 
the activity of small clusters of neurons with fluorescence calcium imaging23-25. On average 7±2 6 
fluorescent neurons (n=26 fields), stained with the membrane permeable Ca2+ dye Fura-2-AM 7 
(see Supporting Information), were simultaneously visualized in the recorded field (120 x 160 8 
µm2). We compared and characterized the cell ability to generate repetitive Ca2+ oscillations23-25. In 9 
control conditions all recorded fields (n=8) displayed active cells, while in s-GO treated cells 10 
56% (n=10 out of 18) of the recorded fields did not display detectable cell activity. However, in 11 
the remaining s-GO fields (n=8), we found an amount of neurons that were spontaneously 12 
generating repetitive Ca2+ oscillations comparable to that measured in controls (Figure 2 (b), 36% 13 
in control, 20 out of 56 neurons, n=8 active fields and 30% in s-GO-treated, 18 out of 60 14 
neurons, n=8 active fields).  15 
 Figure 2 (b) traces represent fluorescence recordings from active fields in control and s-16 
GO-treated cultures (2 sampled cells in each field). Episodes usually comprised spontaneous 17 
bursts of activity, fully blocked by tetrodotoxin (TTX,, a blocker of voltage-gated, fast Na+ 18 
channels) applications (1 µM; n= 8 fields, control and s-GO-treated; not shown). Control Ca2+ 19 
oscillations displayed an inter-event interval (IEI) of 36 ± 2 s (n=20 cells) that was significantly 20 
lower (P < 0.001; Student’s t-test) than that measured in s-GO-treated networks (110 ± 6 s, n=18 21 
cells, right plot in Figure 2 (b)). When GABAA receptors were pharmacologically blocked by 22 
bicuculline (20 µM; 20 min), an antagonist of inhibitory connections known to potentiate 23 
rhythmic activity patterns23,26,27, the control IEI average value was still significantly lower (P < 24 
0.001; Student’s t-test) than that measured in s-GO neurons in the presence of the GABAA 25 
receptor antagonist (18 ± 1 s, n = 20 control cells, vs 92 ± 10 s, n = 18 s-GO cells; plot in Figure 26 
2 (b), right). This indicated a direct reduction in the excitatory activity due to s-GO exposure. 27 
 Next we recorded single cell synaptic activity in the presence of TTX (1 µM, Figure 3 28 
(a)). Under these experimental conditions synaptic currents, termed miniature PSCs (mPSCs), 29 
do not depend on action potential generation. mPSCs are due to the stochastic fusion of 30 
neurotransmitter vesicles at the presynaptic membrane and their frequency is proportional to the 31 
number of synaptic contacts28. Despite the fact that in the recorded hippocampal neurons 32 
spontaneous synaptic activity was manifested as inward currents (in our recording conditions, 33 
see Supporting Information21) made up by a mixed population of inhibitory (GABAA receptor-34 
mediated) and excitatory (AMPA glutamate receptor-mediated) PSCs, virtually all mPSCs, as 35 
previously reported22, were identified as excitatory by their fast kinetics (decay time constant τ= 36 
 10 
4 ± 0.3 ms, see Supporting Information22). Notably, s-GO significantly decreased (P < 0.001, 1 
Student’s t-test; see plots in Figure 3 (a)) the frequency of mPSCs without affecting their 2 
amplitude (0.06 ± 0.02 Hz and 30 ± 0.7 pA, control, n = 15; 0.02 ± 0.001 Hz and 26 ± 0.7 pA, s-3 
GO-treated n= 9; summarized in Figure 3 (a)). To ascertain whether the s-GO interference with 4 
synaptic activity was selective on glutamate-mediated fast synaptic transmission, we tested the 5 
occurrence of evoked inhibitory PSCs by pair recordings of mono-synaptically coupled neurons22 6 
(Supplementary Information and Figure S6a) and we observed that s-GO apparently did not 7 
impair GABAA mediated connections. 8 
 To determine whether changes in excitatory synaptic density may account for the 9 
reduction in fast- mPSC frequency detected in s-GO treated cultures, neurons were co-10 
immunostained for β-tubulin III and the vesicular glutamate transporter (VGLUT1), a 11 
transmembrane protein localized at the glutamatergic presynaptic terminals29. Antibody to 12 
VGLUT1 labeled presynaptic boutons under both conditions (Figure 3b). Using β-tubulin III 13 
labeling to identify neuronal bodies and dendrites, we quantified VGLUT1-positive puncta, 14 
detecting a significant (P < 0.001; Student’s t-test) reduction in their density in s-GO treated 15 
samples (control 1.4 x 10-3 ± 0.045 x 10-3 n= 6 fields and s-GO 0.28 x 10-3 ± 0.11 x 10-3 n= 6 16 
fields, plot in Figure 3 (b)). Parallel experiments were performed to quantify GABAergic 17 
synapses, by similar co-staining but for the vesicular GABA transporter (VGAT) to localize 18 
presynaptic GABAergic terminals22,30. These studies indicated that s-GO incubation did not alter 19 
the inhibitory connection density (Supporting Information and Figure S6b).  20 
 11 
Figure 3 1 
 2 
Figure 3.  s-GO  exposure at high concentration impaired excitatory synapses. In (a) sample tracings of mPSCs 3 
recorded in control and s-GO-treated cultures (left panel). Right panel: plots reporting mPSC amplitude and 4 
frequency values. s-GO-treatment significantly decreased the frequency of mPSCs (*** = P < 0.001 Student’s-t-5 
test). In (b) confocal reconstruction of control and s-GO treated neurons immunolabeled for the vesicular glutamate 6 
transporter 1 (VGLUT1; green) and counterstained for cytoskeletal component β-tubulin III (red; nuclei are 7 
visualized by DAPI in blue; scale bar 10 μm). The plot shows the significant decrease of VGLUT1-positive puncta 8 
in s-GO-treated cultures (*** = P < 0.001 Student’s-t-test).  In (c) top, fluorescence images following staining with 9 
FM1-43, control and s-GO-treated. Scale bar 50 μm. The areas in the boxes are higher magnifications to highlight 10 
the difference in vesicular staining between the two conditions (scale bar 100 μm). The plot (top right) reproduces 11 
the representative (control and s-GO) traces of FM1-43 de-staining (please note that each trace has been normalized 12 
to the maximum fluorescence detected).  Bottom: the left plot summarizes the initial raw fluorescent intensities of 13 
hippocampal terminals from control and s-GO-treated cultures (** = P < 0.01 Mann-Whitney test); the right plot 14 
summarizes the decay time constant τ of FM1-43 de-staining in the two conditions (*** = P < 0.001, Mann-Whitney 15 
test). 16 
 17 
 12 
 In the next set of experiments we measured the kinetics of synaptic vesicle release by 1 
real-time imaging of vesicles labeled with FM dye to monitor the rate of presynaptic vesicle 2 
recycling from hippocampal neurons treated or untreated with s-GO. After staining with the 3 
lipophilic dye FM1-4331-33 clusters of presynaptic terminals were visible as bright fluorescence 4 
spots (Figure 3 (c)). The fluorescence intensity measured on FM-positive puncta following high 5 
KCl (50 mM;34 ) depolarization is proportional to the number of vesicles endocytosed during 6 
synaptic vesicle recycling, and thus, allows to estimate the size of the recycling vesicle pool34. In 7 
s-GO treated cells, upon high-K+-loading protocol, we detected a significant (P < 0.01; Mann-8 
Whitney test) reduction in the raw fluorescence intensity of FM1-43-positive hippocampal 9 
terminals (control 11876 ± 1100 arbitrary units –a.u.-, n= 7 fields; s-GO-treated 7400 ± 1057 10 
a.u., n= 6 fields; 3 different culture series; Figure 3 (c)), suggesting that chronic incubation with 11 
s-GO decreased the recycling vesicle pool. When analyzing the decay time constant (τ) of the 12 
FM1-43 fluorescence de-staining profiles during vesicle exocytosis, we observed a significant 13 
(P < 0.001; Mann-Whitney test) difference in the kinetics displayed by control (τ= 5.7 ± 0.5 s, n 14 
= 205 terminals) and s-GO (τ= 18 ± 2 s, n = 85 terminals) treated cells, as summarized in Figure 15 
3 (c). In reference experiments, image series captured on FM1-43 stained cells but without the 16 
high-K+ de-staining stimulus, produced a baseline reference plot (not shown). Taken together, 17 
these results support the specific ability of chronic exposure to s-GO flakes to reduce the amount 18 
of excitatory synaptic contacts and to interfere with presynaptic vesicle recycling.  19 
 To test the ability of s-GO to impair cell membrane dynamics in general, we investigated 20 
whether s-GO (10 µg/mL) was also reducing exocytosis and recycling of synaptic-like 21 
microvesicles (MVs15) from cultured primary glial cells (see Supplementary Information). MVs 22 
are released into the extracellular space by direct budding from the plasma membrane of 23 
astrocytes, and have been shown to contribute to intercellular communication15,35,36. We treated 24 
pure glial cell cultures with s-GO (10 µg/mL) for 6-8 days. In Figure 4 (a) immunofluorescence 25 
staining of control and s-GO treated GFAP-positive cells are shown. s-GO incubation did not 26 
affect astrocyte density (Figure 4 (a) right histograms; n= 20 fields for both conditions) 27 
excluding any cytotoxic effect. In glial cultures MVs release was induced by bzATP incubation 28 
(100µM, 30 min, n= 3 different series of cultures37-39), and MVs release was detected and 29 
quantified by immunoblot analysis of the collected supernatant. In control, bzATP stimulation 30 
induced the appearance of the band corresponding to flotillin-1 (Figure 4 (c), bottom blot), a 31 
signature of MVs release40-42. Surprisingly, in s-GO treated astrocytes, the bzATP stimulation 32 
induced a marked increase in the size of the flotillin-1 band. This band was also detected in the 33 
absence of stimulation (Figure 4 (c) bottom blot) suggesting that s-GO per se induced MVs 34 
constitutive release.  35 
 13 
 AFM micrographs, show in Figure 4 (b) (left panel) the presence of vesicles in the 1 
stimulated control supernatant appearing as circular spots protruding from the ultra-flat mica 2 
surface. For each of them, width and height were independently measured from particle crossing 3 
height profiles and the resulting distributions were plotted (Figure 4 (b) right panel). 4 
Intriguingly, similar experiments with GR (10 µg/mL) did not induce shedding of MVs in glial 5 
cell cultures (Supplementary Information and Figure S7).  6 
We also attempted to investigate the effect of increased lateral size of GO (l-GO, with a 7 
lateral dimension in the few µm range; 10 µg/mL final concentration) on cultured hippocampal 8 
cells. However, after 6-8 days of incubation, we measured a significant (P < 0.001; Student’s t-9 
test; Figure 4 (d)) reduction in both neuron and glial cell densities (control 160 ± 10 10 
neurons/mm2 and 96 ± 10 astrocytes/mm2; l-GO-treated 96 ± 10 neurons/mm2 and 40 ± 7 11 
astrocytes/mm2; n=10 visual fields each, 3 series of cultures; Figure 4 (d)) indicating cell toxicity 12 
that prevented any further functional measurements. We believe further investigations are 13 
warranted to explore such lateral size-dependent cytotoxic responses. 14 
 15 
 16 
 17 
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Figure 4 1 
 2 
 3 
Figure 4.  s-GO exposure and microvesicles release in glial cells. In (a) immunolabeling of primary rat astrocytes 4 
(3 weeks) in control and s-GO treated cells (10 μg/mL 6-8 days). Both cultures were immune-stained for GFAP 5 
(green) and nuclei visualized by DAPI (blue; scale bar: 100 μm). No statistical significance was found between the 6 
two conditions (top right). In (b) AFM image of fixed MVs where the differences in color are representative of 7 
height differences (brighter means higher). A representative height profile crossing 3 MVs is reported. The scatter 8 
plot (right) shows MVs width versus height distribution and is fitted with a regression line represented by the 9 
equation y = 0.046x + 0.218. A frequency histogram, built upon experimental measurements of both width and 10 
height, was plotted over each axis of the scatter graph, and fitted with Gaussian distributions. The frequency 11 
histograms revealed the highest number of occurrences to be about 490 nm and 24 nm for width and height, 12 
respectively. In (c) Western blotting of the pellets (bottom row) and cell lysates (top row) for the MVs marker 13 
flotillin-1. Pellets were obtained from the medium of glial cultures treated or un-treated with s-GO, under 2 different 14 
conditions: stimulated and not stimulated (Krebs) by 100 μM BzATP.  Note the marked increase of the band for 15 
flotilin-1 in s-GO treated cells. In (d) plots summarizing the decreased density of hippocampal cells when treated 16 
with L-GO (~ 10 µm lateral size; 10 µg/mL final concentration). 17   18 
 15 
We report here the ability of s-GO nanosheets to interfere specifically with neuronal 1 
synapses, without affecting cell viability. In particular, in cultured neuronal networks, upon 2 
chronic s-GO exposure, glutamatergic release sites were sized down. This was shown by: i) the 3 
reduction in frequency of spontaneous synaptic activity (PSCs and mPSCs) together with the 4 
marked reduction in VGLUT1-positive labeling43, ii) the reduced probability of finding active 5 
neurons when network were explored by Ca++-imaging23,44 and iii) the decreased recycle vesicle 6 
pool quantified by FM1-43 measures together with the altered kinetic of vesicle recycling34. 7 
This down-regulation of glutamate-mediated synapses was apparently not due to a general cell-8 
membrane disruption or to neuronal cell loss. In fact, we never detected alterations in basic 9 
electrophysiological parameters, reflecting neuronal health and membrane integrity18-20. 10 
In addition, cell densities in treated cultures were comparable to control ones. The 11 
survival of GFAP-positive glial cells was also not affected by s-GO exposure, both in mixed 12 
neuronal and in pure neuroglial cultures. In the latter condition, MVs release was indirectly 13 
monitored by the blot analysis of flotillin-1 protein40,41, and MVs presence confirmed by direct 14 
AFM measures. In these cultures, exposure to s-GO stimulated the basal release of shed vesicles 15 
and augmented the bzATP-induced one37-39. s-GO increase in MVs release from neuroglia cells 16 
might be related to a general cell-stress condition15 ultimately due to s-GO glial-membrane 17 
interactions or even internalization, depending on the flakes’ shape, lateral dimension and 18 
oxidization degree10 as well as the degree of protein adsorption from the culturing milieu45. 19 
Based on our experimental evidence we cannot rule out that treatment with s-GO down 20 
regulated the synaptic function (in particular presynaptic release) via MVs released in mixed 21 
neuronal-glial cultures, thus excluding a direct, membrane interference of s-GO nanosheets at 22 
the pre-synaptic glutamatergic terminals. MVs have long been reported as active messengers of 23 
intercellular communication, rather than mere inert debris37, however, to our knowledge, there 24 
are no reports of astrocyte shed-MVs acting as regulators of synaptic activity. On the contrary, 25 
MVs released by microglia have been reported to affect synaptic activity, mainly acting at the 26 
presynaptic site of the excitatory synapses, but increasing synaptic activity and release in 27 
primary cultures37. Against this neuroglial-cell mediated response to s-GO is also the fact that 28 
astrocyte density in mixed cultures is artificially kept at a low level by the culturing procedure in 29 
itself, while the surviving microglia are even fewer46.  30 
 16 
In contrast to s-GO, the inert nature of GR flakes regarding synaptic activity and MVs 1 
release by glia is also of interest. This could be due to differences in shape and lateral size 2 
affecting flake-membrane interactions10. It is also interesting to consider that GR have a much 3 
less hydrophilic surface character and overall poorer dispersibility in cell culture media45 that 4 
may lead to the formation of aggregates potentially unable to interact with sub-microscopic 5 
structures (such as the synaptic clefts).  6 
           The apparent selectivity in terms of the presynaptic terminals targeted by s-GO was also 7 
notable, with the inhibitory, GABAergic ones that remained unaffected, as evidenced by pair 8 
recordings and the VGAT labeling22. Given the ability of graphene flakes to undergo motion and 9 
vibration that can lead to interaction with and possible piercing of lipid bilayers8, we propose an 10 
alternative mechanistic interpretation of our synaptic results. s-GO flakes may prevent the 11 
synaptic vesicle endocytotic cycle because their dimensions allow them to interact with the 12 
presynaptic cell membrane at the periphery of the synaptic cleft and then be up-taken by 13 
vesicles. In this process, the flakes may transiently trap vesicles in an open mode and prevent 14 
their closing and the subsequent endocytosis. This could affect synaptic release in the short term 15 
inducing, in the long term, a down regulation of glutamatergic release sites and synapses. To 16 
note, glutamatergic synaptic activity is specifically affected also when neurons are transiently 17 
exposed to s-GO, with a short-term up-regulation of release, turned into a down regulation 18 
within the first 3 days of chronic exposure (Figure S8 in Supplementary Information).  The 19 
mechanism of such interaction among s-GO flakes and vesicles could be similar to what has 20 
been previously described for dispersed single walled carbon nanotubes47. In this context, the 21 
unlikeliness of affecting GABAergic terminals may reside in the different dimensions of the 22 
excitatory (16 nm) and inhibitory (10 nm) synaptic clefts48. The latter reported to be even 23 
narrowed to 6 nm at the periphery of the clefts due to transcleft elements while docked vesicles 24 
are concentrated at the central cleft domain48. On the contrary, docked vesicles in excitatory 25 
synapses are distributed evenly over the synaptic cleft48. It is tempting to speculate that these 26 
synaptic ultra-structural differences might explain why glutamatergic terminals became ideal 27 
targets to s-GO interactions. This selectivity is supported by the notion that, even when 28 
transiently exposed to s-GO via pressure ejected brief pulses, GABAergic synapses are 29 
unaffected (see Supplementary Information).  30 
 17 
 Regardless of the mechanisms involved, the ability of s-GO to alter synapses and induce 1 
glial cell reaction has not been previously documented. This might compromise neuronal 2 
signaling and CNS functions and seems crucially dependent on the GO sheet dimensions, since 3 
larger flakes were found unequivocally cytotoxic. In our experiments 6 days exposure of cultures 4 
to equal amounts of dispersed l-GO induced unequivocal hippocampal cell loss, both neuroglia 5 
and neurons, thus hampering any further evaluation of membrane/flakes interactions.  6 
These observations deserve further studies, in fact, altering synapses and inducing glia reactivity 7 
may raise concerns from the safety and nanotoxicity point of view49.  8 
Beyond the safe design of nanomaterials, such a subtle interference affecting exquisite 9 
CNS signaling may offer possibilities in neuropharmacology, when specific targeting of 10 
excitatory synapses is desired50-52. The use of nanoparticles as therapeutics is in fact fueled by 11 
their ability to circumvent biological barriers53 and targeting of synapses has created the basis for 12 
theranostics applications54. Our observations with thin s-GO flakes illustrate the potential of 2D 13 
nanosheet physical properties to engineer novel and specific glutamate-transmission modulators.  14 
It is also relevant to note that synapse formation and function in neuronal networks, when 15 
interfaced to planar graphene-based materials, are not affected55. This strengthens the notion that 16 
when exploring the application of graphene in biology, studies should be performed with well-17 
characterized types of materials, since the materials’ physical-chemical features, including 18 
geometry, are governing the potential interactions with specific biological components2.	19 
 20 
Methods 21 
Materials and Methods are described in the Associated Content and Figures 22 
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